Elicio reports ELI-002 Phase 1 data: 87% T cell response, 86% reduced relapse risk; new preclinical data

Elicio Therapeutics, Inc.

ELI-002 Phase 1: 87% (20/23) of patients had direct ex vivo mKRAS-specific T cell responses; 100% in vitro.
T cell response strength correlated with 86% reduced risk of relapse and death in pancreatic/colorectal cancer.
In 4 patients assessed post-boost, 100% maintained elevated T cell responses, 75% increased further.
ELI-007 and ELI-008 preclinical: >10-500-fold higher T cell responses vs. conventional comparators in mice.
Data presented at SITC 2023; supports lymph node-targeting AMP platform for solid tumors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.